Trial Profile

A Randomised, Double-blind, Placebo Controlled, Repeat-dose, Cross-over Phase I Study to Evaluate the Pro-arrhythmic Potential of GSK3039294 in Healthy Participants

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 3039294 (Primary)
Indications Amyloidosis
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

05 Oct 2018 Planned End Date changed from 2 May 2019 to 3 May 2019.
05 Oct 2018 Planned primary completion date changed from 2 May 2019 to 3 May 2019.
05 Oct 2018 Planned initiation date changed from 11 Jul 2018 to 12 Jul 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com